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In situ immune complex formation and glomerular injury
Most forms of glomerulonephritis (GN) are be-
lieved to result from antibody deposition within the
glomerulus activating secondary mediators of tissue
injury including complement (C), neutrophils, coag-
ulation factors [I], and mononuclear cells of bone
marrow origin [2, 3]. Immune deposits most com-
monly occur in a discontinuous, granular, or "lum-
py-bumpy" pattern, now considered pathogno-
monic of glomerular immune complex (IC) deposi-
tion [4, 5]. By immunofluorescent (IF) and electron
microscopy (EM), IC deposits are detected in the
mesangium in early lupus GN, IgG-IgA nephropa-
thy, Henoch-Schönlein purpura, and other dis-
eases; in the subendothelial space between endo-
thelial cells and glomerular basement membrane
(GBM) in the proliferative forms of lupus GN and
type I membranoproliferative GN; or in the sub-
epithelial space and filtration slit pores as "humps"
in poststreptococcal GN or as the diffuse, finely
granular deposits characteristic of membranous ne-
phropathy (MN) [6]. Based primarily on studies in
the acute and chronic serum sickness models in rab-
bits, it is now widely accepted that these deposits
result from trapping of immunoglobulin in the form
of preformed, soluble IC's derived from the circula-
tion, with the glomerulus viewed largely as an in-
nocent bystander [5, 6]. The type of GN produced is
dependent on the site and quantity of IC's deposited
as influenced by several systemic factors including
IC size determined by antigen-to-antibody ratio [6-
8] and lattice formation [9—11], reticuloendothelial
(now mononuclear phagocyte) system function [11-
14], serum IC levels [15], vasoactive amine activity
[16-18], and hemodynamic and pharmacologic fac-
tors [8, 15, 16, 19, 20]. The discovery of the associa-
tion between IC's formed in the circulation and the
development of glomerular immune deposits is
clearly the most significant single contribution yet
made to the understanding of immunologically-me-
diated renal diseases. The CIC trapping mecha-
1
nism, however, does not fully account for the
marked variability in histologic and clinical features
of different forms of GN associated with IC deposits
nor does it accord with recent findings in models of
immune complex glomerulonephritis (ICGN) other
than serum sickness or the poor correlation be-
tween circulating IC (CIC) measurements and gb-
merular immunopathology in some human gbomeru-
lar diseases.
Recent studies now provide strong evidence for a
second mechanism of granular immune deposit for-
mation in glomeruli —that is, the reaction of free cir-
culating antibody with antigens already present or
fixed in the glomerulus by mechanisms that reflect
properties of the glomerulus itself and result in in
situ deposit formation [2 1—23]. In situ complex for-
mation is an established cause of tissue injury in
several other organs, including the thyroid [24] and
testes [25], and may cause immunologically-mediat-
ed tubulointerstitial disease in the kidney [26, 27].
Most forms of ICGN have previously been re-
garded, however, as diseases of CIC trapping, and
in situ IC formation has not generally been accord-
ed an important role in their pathogenesis. It is our
purpose here to examine the evidence that now sup-
ports a role for in situ IC formation in experimental
glomerular disease, to review the mechanisms by
which this form of immune reaction may induce gb-
merular injury, and to consider the possible role of
this mechanism in the pathogenesis of ICGN in
man.
Historical perspective
Since the observations of Schick and Von Pirquet
that GN following streptococcal infections and sen-
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sitization to foreign serum proteins, respectively,
ensued only after a latent period [28, 29], it has been
widely held that GN resulted from some form of
antibody-mediated hypersensitivity reaction, a
view supported by the development of IF micros-
copy and the demonstration of immune deposits in
diseased glomeruli [30, 3111. Because tissue damage
was then believed to result only at the site of anti-
gen-antibody interaction, as in the Arthus reaction
[32], most workers postulated that nephritogenic
antigens must first fix in tissue before reacting with
antibody to produce disease [33—35]. This view,
however, was largely abandoned for ICGN by 1960,
when extensive studies of the serum sickness mod-
els in rabbits by Germuth et al and Dixon et al had
provided compelling evidence that glomerular in-
jury in these models resulted from deposition of
IC's formed in the circulation. In the acute "one-
shot" serum sickness model, glomerular deposits
and GN developed coincident with immune elimina-
tion of injected antigen [36-39] and appearance of
antigen in IC form in the circulation [5, 6, 39]. The
glomerular deposits contained the same antigen
present in the CIC's, and no antigen deposits were
demonstrable prior to antibody deposition [39]. In
some animafs with acute serum sickness, the sub-
epithelial deposits observed closely resembled the
"humps" seen in poststreptococcal GN in man
[40]. In chronic serum sickness, induced by repeat-
ed administration of a constant dose of antigen, the
site of glomerular deposits was largely dependent
on the antibody response [6]. Vigorous responders
developed antibody excess aggregates and no de-
posits, moderate responders developed smaller,
more soluble IC's and mesangial and subendothelial
deposits, and poor antibody responders remained in
persistent antigen excess and formed small, soluble
IC's of about 300,000 to 500,000 daltons associated
with subepithelial deposit formation [6]. If, how-
ever, the antigen dose was adjusted to balance cir-
culating antibody and maintain a state of chronic
antigen excess, deposits localized almost exclusive-
ly in the subepithelial space regardless of the level
of antibody response [5, 7, 41]. Because the mecha-
nism of deposit formation at all sites in the two
models was presumed to be similar, the sub-
epithelial deposits characteristic of chronic serum
sickness were believed to reflect the ability of small
CIC's to penetrate the capillary wall and to be
trapped or precipitate in the subepithelial space and
filtration slits [1, 5, 6, 41], a view subsequently ex-
tended to human diseases with similar immuno-
pathologic features [6, 42].
Although CIC deposition has never been directly
demonstrated in serum sickness, attempts to docu-
ment such a phenomenon have been made by im-
munizing mice with the electron-dense antigen fern-
tin [43, 44]. In these studies, ferritin IC's were ob-
served at times in the circulation and localized in
mesangial, subendothelial, and subepithelial areas,
as well as within the GBM [43, 44]. Although it
was concluded that the IC's within the GBM
represented circulating IC's crossing the capillary
wall to form the subepithelial deposits, this se-
quence was not documented. The possibility that
some free ferritin, perhaps more cationic molecules
(see below), penetrated the GBM and reached
the subepithelial space to initiate local IC formation
was not considered at the time, although the
animals were clearly in substantial antigen excess
during portions of the studies [44]. However,
these reports currently represent the only published
claim to demonstrate experimentally the trans-
capillary passage of preformed CIC's to form sub-
epithelial immune deposits.
Studies of preformed immune complex localization
Many attempts to study glomerular injury due to
CIC deposition have been made by infusing pre-
formed IC's into various animals. Germuth and
McKinnon [45], and McCluskey and Benacerraf
and coworkers [46-50], reported mild GN associat-
ed with granular deposits containing both com-
ponents of the administered preformed IC's which
apparently did not dissociate after injection [47].
These and later studies in which IF, EM, or both,
have been used to study the glomerular localization
of preformed IC' s or protein aggregates of similar
size and properties are summarized in Table 1. Nu-
merous studies failed to achieve glomerular local-
ization of IC's, probably because of insufficient size
or dose of the IC's infused [17—19, 51—53]. The size
of CIC's required for tissue localization in acute
serum sickness was determined by Cochrane and
Hawkins to be l9S or greater [8], whereas rabbits
with chronic serum sickness and subepithelial de-
posits generally had CIC's in the 15S size range [6].
Haakenstad et al found that glomerular deposition
of large lattice IC's (> 1 iS) could be achieved with
large IC doses or inhibition of mononuclear phago-
cyte system clearance, but that deposits were found
only in subendothelial and mesangial sites [9, 10,
13]. Most studies in which glomerular localization
has been studied by IF alone have observed mesan-
gial localization of deposits almost exclusively [10,
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Table 1. Studies of glomerular localization of preformed immune complexes and protein aggregatesa
Methods of
Report Material injected localization Results
Imnune complexes
Mellors, 1962 [54] Rabbit anti-BSA or OA-FITC IC's into mice IF Mesangial deposits, BSA-FITC IC's
and BSA-FITC alone on capillary wall
McCluskey, 1962 [50] Rabbit anti-DNP-DNP-BGG IC's to mice IF Mesangial deposits
Weiser, 1962 [55] Rabbit anti-BSA IgG-FITC-BSA IC's to mice IF Diffuse" glomerular deposits, no illustrations
Okumura, 1971 [59] Rabbit anti-BSA IC's to mice IF, EM Mesangial and subendothelial deposits
Wright, 1973 [61] Dog anti-canine adenovirus IC's to mice IF, EM Mesangial and subendothelial deposits
Haakenstad, 1975 [13] Rabbit anti-HSA IC's to mice IF Mesangial deposits
Ford, 1975 [12, 56] Rabbit anti-BSA IC's to mice IF Mesangial deposits, mesangial and capillary
Haakenstad, 1976 [10] Rabbit anti-HSA IC's to mice IF, EM
wall deposits with RES blockade
Mesangial and subendothelial deposits
Van Damme, 1978 [22] Rabbit anti-rat FxIA IC's to rats IF Mesangial deposits
Koyama, 1978 [60] Rabbit anti-DNP-BSA or BGG to mice IF, EM
Rabbit anti-TNP BSA
Mesangial and subendothelial deposits
Michael, 1967 [62]
Protein aggregates
Aggregated HSA, IgG to mice IF, EM Mesangial and subendothelial deposits
Mauer, 1972 [63] Aggregated IgO to rabbits IF Mesangial and subendothelial deposits
Ford, 1975 [64] Aggregated BSA to mice IF Mesangial and "pericapillary" deposits
Kijlstra, 1978 [65] Aggregated 1gM IF, EM Mesangial and subendothelial deposits
a Abbreviations are: BOG, bovine gamma globulin; DNP, dinitrophenol hapten; FITC, fluorescein isothiocyanate conjugated; HSA,
human serum albumin; OA, ovine albumin; TNP, trinitrophenol hapten; RES, reticuloendothelial (mononuclear phagocyte) system.
11, 13, 22, 50, 54—56] (Table 1). Fluorescein-con-
jugated bovine serum albumin (BSA) IC's were re-
ported along the glomerular capillary wall by Mel-
lors and Brzosko, but a similar pattern was reported
with fluorescein-conjugated BSA alone, and no EM
studies were performed [54]. Van Damme et al ad-
ministered preformed IC's of IgG and rat tubular
antigen and found only mesangial deposits [22], al-
though rats actively or passively immunized to this
same antigen have deposits exclusively in the sub-
epithelial space [57, 58]. EM studies of preformed
IC localization have also identified deposits only in
the mesangial and subendothelial areas (Table 1)
[10, 59—61]. Koyama et al produced subendothelial
localization of BSA-hapten IC's in mice by injecting
IC's of moderate affinity antibodies or low valency
antigens [60]. When antibody avidity or antigen va-
lence were further reduced, however, no glomeru-
lar localization occurred, and higher affinity or va-
lence IC's were deposited only in the mesangium.
Similar results have been obtained using aggregates
of various serum proteins in the size range of IC's
(Table 1) [62—65].
The inability to produce subepithelial deposits
similar to those in chronic serum sickness by pre-
formed IC infusion stimulated a search for factors in
actively immunized animals that might facilitate
transcapillary passage of CIC's. Kniker and Coch-
rane demonstrated that vasoactive amine antago-
nists blocked glomerular IC deposits in acute serum
sickness [16]. Increased vascular deposition of pre-
formed IC's was achieved in animals pretreated
with agents which release endogenous histamine,
but these agents did not significantly increase gb-
merular deposits [17, 18]. Moreover, vasoactive
amine blockade has generally had little consistent
effect in decreasing subepithelial deposits in chronic
serum sickness [66] or in rat models with similar de-
posits [67—69], although other studies showing some
benefit have also been reported [70-72]. Maneuvers
to increase glomerular permeability by using other
agents have reduced rather than increased sub-
epithelial deposits (see below) [21, 69]. Thus, al-
though the ability of preformed IC's to deposit in
the mesangium and subendothelial areas is well es-
tablished, to date no study of preformed IC's or ag-
gregates has demonstrated subepithelial local-
ization in vivo (Table 1).
Nonmembranous in situ glomerular
im,nune complex formation
Although it has long been accepted that the linear
deposits of IgG characteristic of anti-GBM disease
result from direct binding of circulating antibody to
antigens localized within the glomerular capillary
wall, the first demonstration that a common type of
granular deposit in a glomerulus could result from a
similar mechanism was provided by Mauer et al in
1973 [73]. In their studies, injection of heat-aggre-
gated human IgG into rabbits resulted in mesangial
localization of the aggregates. When rabbit kidneys
containing mesangial deposits of human IgG were
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transplanted into normal recipients that were then
given antibody to human IgG, the mesangial depos-
its served as a "planted" antigen, which bound cir-
culating antibody, resulting in local IC formation, C
activation, and histologic evidence of acute GN
[73]. These studies demonstrated that mesangial IC
deposits could result from either CIC (aggregate)
trapping or local IC formation. Golbus and Wil-
son used the glycoprotein-binding properties of
the plant lectin concanavalin A (con A) to produce
nonimmunologic attachment of this antigen to the
glomerular capillary wall [74]. Subsequent per-
fusion with antibody to con A resulted in locally
formed deposits of IgG and C and a proliferative
GN. The exact site of IC formation in this model
has not been established but is believed to occur in
part in subendothelial areas. Of particular interest
with respect to disease in man are the studies of
Izui, Lambert, and Miescher that demonstrated that
free DNA will bind avidly in vitro to collagen and
collagen-like structures in isolated GBM [75]. DNA
binding was inhibited by low pH, low ionic
strength, and anionic detergents, suggesting a
charge interaction. Addition of anti-DNA antibody
resulted in in situ DNA-anti-DNA IC formation on
the GBM [75]. These studies illustrate two mecha-
nisms by which glomerular localization of non-
glomerular antigens may occur prior to in situ IC
formation, that is, mesangial uptake of antigen and
nonimmunologic binding of antigen to normal gb-
merular consituents.
In situ deposit formation in the subepithelial space
Recent studies in rat models with subepithelial
immune deposits identical to those in chronic sick-
ness have apparently identified a third mechanism
for in situ glomerular IC formation. Rats immunized
with an antigen derived from the luminal brush bor-
der of proximal tubular epithelial cells (FxlA) [76]
develop proteinuria and subepithelial immune de-
posits indistinguishable from those in MN in man
(Heymann nephritis, autologous IC nephropathy
[AICNJ) [57, 77]. The authors of earlier studies sug-
gested that AICN may involve loss of tolerance to
tubular antigen [78, 79], which normally circulates
in nanogram quantities [79-8 1], antibody formation,
and chronic formation and deposition of small
CIC's containing tubular antigen. Tubular antigen
has recently been identified in CIC's in AICN rats
by Abrass, Border, and Glassock [82] and is present
in glomerular deposits in AICN [78, 79]. The immu-
nologic characteristics of the AICN model, how-
ever, are difficult to reconcile with a CIC pathogen-
esis. In AICN subepithelial deposits develop in
marked antibody excess [21, 81, 83] when antigen is
virtually absent from the circulation [81]. Unless
the number of antigenic determinants involved are
very limited, this situation should result in forma-
tion of large IC's that would localize in the mesan-
gium or outside of the kidney rather than exclusive-
ly in the subepithelial space as observed [57].
Evidence for an in situ mechanism for the forma-
tion of subepithelial deposits has derived largely
from recent studies in the passive Heymann nephri-
tis (PHN) model in which a lesion identical to AICN
is produced in hours by administration of heterolo-
gous antibody to Fx1A [58, 84]. Studies of the autol-
ogous phase of this model demonstrated that rat
IgG can deposit in a membranous pattern by bind-
ing in situ to granular deposits of heterologous anti-
body already present in the subepithelial space, al-
though the latter deposits were believed to result
initially from CIC trapping [85]. In 1978, Van
Damme et al exposed anti-Fx IA antibody in vitro to
enzyme- or acid-treated normal rat kidney sections
and demonstrated gbomerular antibody binding in a
granular pattern [22]. Moreover, when anti-FxLA
IgG was perfused into a bloodless rat kidney and
localized by an immunoperoxidase EM technique,
antibody binding throughout the glomerular capil-
lary wall, including the subepithelial space and slit
pores, could be demonstrated [22]. Similar results
with antibody eluted from AICN rat kidneys were
reported subsequently [86].
We further investigated the mechanism of sub-
epithelial deposit formation in PHN in vitro using
an isolated perfused rat kidney system [23]. Iso-
lated rat kidneys were perfused for up to 2 hours
at a carefully controlled temperature, pressure,
pH, and flow rate with purified 7S anti-FxIA IgC
or control nonantibody IgG, in an oxygenated
synthetic perfusate that contained only BSA in
physiologic buffer. To avoid tubular antigen enter-
ing the perfusate from the perfused kidney, we
used a "single-pass" system with renal venous ef-
fluent run to waste. Granular deposits of IgG were
demonstrated along capillary walls within 10 mm
by IF and a membranous pattern of antibody depos-
its similar to that seen in vivo developed by 2 hours
[23] (Fig. 1). Conventional EM revealed small de-
posits only in the subepithelial space and slit pores
(Fig. 1) [23]. Control perfusions with nonantibody
IgG produced no gbomerular deposits.
These studies suggest that normal rat glomeruli
possess antigenic determinants capable of directly
binding free anti-Fx1A antibody to produce granu-
In situ co,nplexformation 5
Fig. 1. EM and IF photomicrographs from an isolated rat kidney
perfused with sheep 7S IgG antibody to rat FxIA in buffered a/-
burn in solution. A Several small electron-dense subepithelial
deposits are present after 2 hours of perfusion (black arrows).
BM is basement membrane; EP, epithelial cell. (Magnification,
x 38,000) B After only 10 mm of perfusion, sheep IgG is deposited
in a finely granular pattern (white arrows) along the subepithelial
surface of the capillary wall. Kidneys perfused with non-anti-
body IgG had no glomerular deposits by IF or EM. (Magnifica-
tion, x 630)
tar subepithelial deposits in situ in the absence of
CIC's [22, 23]. Quantitative confirmation of the
presence of such an antigen has been obtained by
demonstrating binding or radiolabeled anti-Fx1A
IgG in vitro to preparations of whole glomeruli simi-
tar to the binding observed with anti-GBM antibody
(Fig. 2) (Salant, Darby, and Couser, submitted for
publication))
Glotnerular properties determining sit bepitlielial
deposit formation
Several properties of the glomerulus itself may
contribute to in situ glomerular IC formation. Thus,
alterations in mesangial function may increase the
uptake of macromolecules, which could serve as
planted antigens [63, 87]. The formation of con A
and DNA IC's on the capillary wall results from the
affinity of these antigens for glomerular glycopro-
teins and charged structures, respectively [74, 75].
In the rat models of MN, the antigen which initiates
in situ subepithelial IC formation appears to be a
We and others demonstrated specific binding of eluate from
AICN rat kidneys to isolated rat glomeruli in vitro (NEALE TJ,
WILSON CS: Abst A,n Soc Nephrol, 1979, p. 29).
Fig. 2. Quantitation by radiolabeling of in vitro binding of nor-
mal sheep '251-IgG, anti-Fx1A '251-IgG, and anti-GBM '251-IgG to
isolated rat glomeruli free of tubular contamination after 21
hours of incubation. Values represent the means SEM.
fixed constitutent of the normal capillary watt im-
munologically cross-reactive with antigens in proxi-
mal tubular brush border [22, 23]. It is likely that
filtration properties of the glomerulus may also con-
tribute to deposit formation in the subepitheliat
space.
The importance of glomerular properties in sub-
epithelial complex formation is clearly illustrated
when glomerular damage and proteinuria are in-
duced by pretreating rats with aminonucleoside of
puromycin (PA) or nephrotoxic serum (NTS) prior
to deposit formation. If unilateral PA nephrosis is
produced by selective PA perfusion of the left kid-
ney of AICN rats before IC deposits occur, sub-
epithelial deposits develop normally in the non-
perfused right kidney but are not found in the ne-
phrotic left kidney of the same animal [21].
Proteinuric left kidneys of AICN rats also demon-
strate mesangial deposits of IgG and FxlA [21],
similar to those reported following infusion of pre-
formed Fx1A IC's [22], which presumably reflect
CIC's in AICN rats [82]. Similar results are seen in
PHN rats and when proteinuria is induced with
nephrotoxic serum rather than PA [69, 88].
The reduction in deposit formation in proteinuric
kidneys parallels the reduction in glomerular affini-
ty for polycationic stains, suggesting that determi-
nants of capillary wall charge may also be factors in
subepithelial immune deposit formation [21, 69, 88].
Other observations support this suggestion. The
concentration and distribution of anionic sites in the
Normal sheep I9G
Sheep anti-rat Fxl A igG
Sheep anti-rat GBM IgG
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lamina rara externa and on the epithelial aspect of
the GBM correspond closely to that of early im-
mune deposits in AICN [57, 89, 90]. Perfusion with
cationic protamine followed by heparin results in in
situ formation of protamine-heparin complexes on
the basis of charge interaction throughout the GBM
and particularly in a subepithelial distribution [91,
92]. Seiler and Hoyer have recently reported a
marked reduction in capillary wall localization and
an increase in mesangial content of protamine-hepa-
rin complexes in PA nephrotic kidneys [93]. These
changes closely parallel the reduction in anionic
sites reported with PA [90] and the reduction in im-
mune deposits in PA kidneys [20, 69] and suggest
that the altered localization of immune deposits in
PA kidneys may also reflect changes in electrostatic
characteristics of the glomerulus. In the AICN and
PHN models in rats, the fixed glomerular antigen
that initiates antibody binding in the subepithelial
space may be related to an anionic site such that
alterations in charge and antigenicity occur simulta-
neously, resulting in reduced deposit formation. In
other circumstances, charge factors may contribute
to subepithelial complex formation by their role in
regulating transcapillary passage and selective re-
tardation of potentially antigenic macromolecules in
the epithelial space and slit pores, where they can
serve as planted antigens to initiate complex forma-
tion at this site [94]. In contrast, in acute serum
sickness, proteinuria induced by IC deposits or
NTS increases rather than decreases glomerular IC
deposits [7, 95].
Mechanisms of proteinuria in experimental
mernbranous nephropathy
Although there is now evidence that immune de-
posits in anti-GBM nephritis (nephrotoxic nephritis
[NTN]) and in experimental MN in the rat both
form in situ, important differences appear to exist in
the kinetics of heterologous antibody deposition
and the mechanisms by which antibody deposits in-
duce proteinuria in the two models. Quantitative
studies of kinetics of heterologous antibody deposi-
tion in vivo in PHN reveal that a significant amount
of binding occurs immediately, as it does in NTN
[96—98]. Enlargement of subepithelial deposits and
deposition of sufficient heterologus antibody to in-
duce proteinuria in PHN occur, however, gradually
over days, regulated by additional factors which
have not been defined [96, 97]. The amount of heter-
ologous antibody deposited in rat kidneys at the
time proteinuria occurs, about 200 j.g, corresponds
closely with the amount of anti-GBM antibody re-
quired to induce proteinuria in the rat (150 to 175
pg), although antibody binding and proteinuria in
NTN occur almost immediately [96-98].
Preliminary studies indicate that proteinuna in
PHN is C-dependent, although C3 depletion does
not reduce complex formation [97, 99]. Thus, the
C3 receptors demonstrated on the epithelial cell
surface in human glomeruli [100] and postulated to
play a role in subepithelial IC localization [101] ap-
parently are not involved in deposit formation in ex-
perimental MN. Of interest is the finding that C-de-
pendent proteinuria in PHN is neutrophil-independ-
ent [97, 99]. This is consistent with the absence of
neutrophils from glomeruli in MN and may reflect
sequestration of C3-containing immune deposits
from circulating neutrophils. Because, however,
the only documented role for C3 in mediating pro-
teinuria in experimental ON is through attraction of
neutrophils [102-104], the C3-dependent, neutro-
phil-independent proteinuria in PHN may reflect a
new role for the complement system in mediating
glomerular injury. The mechanism of proteinuria in
MN may also differ from that in NTN with respect
to the role of charge alterations. In NTN histochem-
ical and physiologic studies suggest that proteinuria
may in part reflect a loss of net negative charge on
the capillary wall [105, 106]. In AICN and PHN, no
loss of staining for glomerular polyanion is apparent
until after proteinuria develops [57, 69], and frac-
tional clearances of anionic, neutral, and cationic
forms of the protein tracer horseradish peroxidase,
all about 30 A in molecular radius, are increased in
similar amounts [107]. These studies suggest that
the proteinuria that results from subepithelial anti-
body deposits may reflect changes in sieving prop-
erties more than altered charge characteristics of
the glomerular capillary wall.
Circulating immune complex measurements in man
Although the recent development of assays for
CIC's has allowed correlation of CIC levels with
glomerular immunopathology in man, the results to
date have not further clarified the pathogenesis of
IC nephritis. The present status of CIC measure-
ments in glomerular disease has recently been re-
viewed by Border [108]. CIC's have been found reg-
ularly in the absence of glomerular immune deposits
in glomerular diseases such as lipoid nephrosis [109,
110], and in a variety of disorders, such as cancer
and liver disease, not generally associated with
ICON [lii, 112]. There therefore appears to be no
consistent relationship between increased CIC re-
activity and development of glomerular immune de-
In situ complex for,nation 7
posits. With regard to subepithelial immune depos-
its, CIC's have been reported in post streptococcal
GN [108, 113-117] but are equally prevalent in
streptococcal sequelae not associated with GN
[1161. The published results of CIC measurements
in patients with idiopathic MN are summarized in
Table 2. Because a recent study comparing 18 meth-
ods for dC detection identified six as being of supe-
rior sensitivity and specificity [118], only reports us-
ing one of these assays to study patients with a well-
established diagnosis of MN are included. Results
have been inconsistent between laboratories, with
the prevalance of CIC's in MN ranging from 0% to
69% [117, 119] (Table 2). Abrass et al in a retro-
spective study tested sera mailed to a central labo-
ratory from multiple centers participating in a col-
laborative study of adult idiopathic nephrotic syn-
drome and found CIC reactivity by two Clq binding
assays in 25 and 40% of 55 patients at the time of
entry into the study [110]. No increased CIC reac-
tivity compared to controls, however, was found by
the Raji cell assay [110]. In other studies using simi-
lar techniques, dC reactivity has been found in on-
ly 7 of 79 patients with idiopathic MN (Table 2)
[115, 117, 120—125]. Zager eta! studied 26 MN pa-
tients prospectively by a Raji cell assay and found
increased reactivity in 6 [125]. Other conditions as-
sociated with increased CIC's, however, were pres-
ent in all 6 patients, including SLE [126], malignan-
cy [1111, transplantation [127], and renal vein
thrombosis [128]. Two patients with gold-induced
MN had no CIC's [125]. One patient with idiopathic
MN who progressed rapidly to renal failure in 3
years and developed recurrent MN 1 week after re-
ceiving a renal transplant had no detectable CIC's
by Raji cell assay before or after the transplant
[129]. Although it remains possible that CIC's in
MN may be present only intermittently, present at
levels below the sensitivity limits of current assays,
or have properties rendering them unreactive by
available detection methods, most recent studies
suggest that CIC reactivity is uncommon in idio-
pathic MN. These observations are consistent with
the hypothesis that subepithelial deposits in MN
may also be formed by an in situ mechanism [130].
In situ formation of subepithelial immune complexes in
,nan
At present there is no conclusive evidence to
document either an in situ IC formation or a CIC
deposition mechanism for glomerular immune de-
posit formation in man, but both seem likely to oc-
cur. In view of the striking correspondence between
the immunohistologic and clinical features of AICN
in rats and MN in man, many attempts have been
made to document a similarity in immuno-
pathogenesis. Tubular antigens have been identified
in capillary wall immune deposits in isolated cases
of nephrotic syndrome associated with hemoglobin-
opathies [131, 132], renal cell carcinoma [133], Fan-
coni syndrome [134], and renal vein thrombosis
[135], and human tubular antigen can induce AICN
in rats [78, 136]. Naruse et al have reported detec-
tion of tubular antigen in glomerular deposits in 4 of
9 patients with idiopathic MN [137, 138], but others
Table 2. Circulating immune complex measurements in patients with idiopathic membranous nephropathya
Report Assay Patients studied No. positive % Positive
Sobel, 1976[119] Clq deviation 26 18 69
Didgeon, 1977 [120] Clq bindinga 10 2 20
Woodroffe, 1977 [1211 Clqbindinga
Raji cell
7
2
1
0
14
0
Ooi,1977[117] Clqbinding 13 0 0
Simpson, 1978 [122) Clq deviation 5 0 0
Tung, 1978[l15] Clq binding"
Rajicell
8
8
0
0
0
0
Robinson, 1978 [1231 Clq bindingb
Raji cell
10
10
2
1
20
10
Rossen, 1979 [124] Clq bindings 9 1 11
Zager, l979[125] Raji cell IS 1 7
Abrass, 1979 [1 IOIC CIq binding8
CIq binding"
Rail cell
55
55
55
22
14
8
40
25
15d
Solid phase assayb Fluid phase assay
Data on entry to nephrotic syndrome studydNot different from control
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have not confirmed this finding [139]. Zager et a!
used a sensitive radioimmunoassay for circulating
antibody to human tubular antigen but were unable
to detect antibody in any of 29 MN patients studied
[125]. Attempts to induce MN experimentally in 6
isolated perfused human kidneys using purified anti-
body to human tubular antigen as reported in the rat
[23] have failed to produce glomerular deposits
(Couser and Salant, unpublished observations).
Thus, although the in situ mechanism for sub-
epithelial immune deposit formation defined in the
rat models of MN seems likely to apply in man as
well, there is little evidence that tubular antigens
commonly play a role in this process.
The possibility that a fixed glomerular antigen
may exist in man that is immunologically unrelated
to tubular antigen but has similar nephritogenic po-
tential has not been excluded. A more likely possi-
bility, however, is one originally favored, by work-
ers in this area over 50 years ago, that is, that non-
glomerular nephritogenic antigens may localize first
in the subepithelial space before binding circulating
antibody to produce insoluble deposits [33]. Con-
siderable evidence developed in the intervening
years is consistent with such a mechanism. Thus,
the studies reviewed above have failed to demon-
strate that preformed IC's can cross the GBM to
localize in the subepithelial space, and indicate that
in actively immunized animals subepithelial depos-
its occur only in the presence of circulating free an-
tigen [5-7]. Although preformed IC's have not been
shown to do so, it is now clear that a variety of po-
tentially antigenic circulating marcomolecules do
cross the GBM and are retarded selectively in the
subepithelial space and filtration slits on a non-
immunologic basis with glomerular charge charac-
teristics playing a major role in this process [94,
140-142]. The few antigens which have been identi-
fied in MN in man such as DNA [143], hepatitis B
virus [144], thyroid [145], and tumor antigens [146,
147] may localize in the capillary wall by similar
nonimmunologic mechanisms as DNA has been
shown to do in vitro [75].2 Ryan et al have shown
that free IgG can penetrate the GBM in vivo if renal
blood flow is reduced [148]. Free, low affinity, cat-
ionic antibody molecules may reach this site under
more normal hemodynamic conditions where gb-
merular ultrafiltration would produce increased an-
tigen-antibody concentration, binding, and precipi-
tation, resulting in in situ IC formation.
2 Fleuren et at showed that alternate perfusion of an isolated
rat kidney with free BSA antigen followed by anti-BSA antibody
resulted in in situ formation of subepithelial immune deposits
containing BSA similar to those in chronic serum sickness, but
that perfusion with preformed BSA immune complexes failed to
produce subepithelial deposits (Kidney Int, in press).
Although the antigen in most cases of MN is not
known, several observations on the immunologic
environment in which subepithelial deposits devel-
op in systemic lupus erythematosus (SLE) are of
interest with regard to the mechanism of IC forma-
tion in man. The studies of Izui et a! demonstrating
binding of free DNA have been reviewed above
[74]. It is known that patients with the membranous
form of lupus nephritis often have low or undetect-
able antinuclear antibody levels [149-151]. Friend
et a! have recently shown that antibody to native
DNA is not only markedly reduced in SLE patients
with membranous compared to proliferative lesions
or no nephritis, but is almost exclusively non-
precipitating [152, 153]. These findings accord with
experimental studies, suggesting that subepithelial
deposits develop more consistently in animals that
synthesize low levels of low affinity antibodies [154,
155]. Thus, in SLE, subepithelial deposits develop
in an immunologic environment in which low levels
of nonprecipitating antibody favor the presence of a
circulating unbound antigen known to be capable of
binding nonimmunologically to GBM. Similarly,
Takekoshi et a! recently demonstrated free hepatitis
Be antigen in the circulation of two patients with
MN associated with glomerular deposits of hepatitis
B antigen [156]. Whether similar conditions are
present in idiopathic MN cannot be determined un-
til the inciting antigens are better defined. The re-
cent finding, however, of Ooi et al that lymphocytes
from patients with idiopathic MN have a significant-
ly reduced capacity to synthesize IgG in response to
a B cell mitogen suggests this possibility [157].
Summary
Recent evidence demonstrates that the granular
pattern of glomerular immune deposits formerly re-
garded as pathognomonic of GN due to trapping of
CIC's may also occur as a result of in situ glomeru-
lar immune deposit formation. Most examples of lo-
cal deposit formation in glomeruli appear to result
from antibody binding to antigens normally present
or previously localized there. Glomerular antigen
localization is largely dependent on properties of
the glomerulus itself, including mesangial uptake,
biochemical, antigenic, and charge characteristics
of the glomerular capillary wall, and possibly filtra-
tion properties. Although localization of preformed
IC's has been well shown to produce mesangial and
subendothelia! deposits, local formation of deposits
at these sites has also been demonstrated. Local-
ization of preformed IC's in a subepithelial distribu-
tion has not been shown to occur. Recent studies of
subepithelial immune deposit formation in rat mod-
els of MN demonstrate that immune deposits at this
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site can form in situ. This is the only mechanism
shown experimentally to produce such deposits. In
the rat, subepithelial complex formation appears to
involve reaction of free circulating antibody with an
antigen normally present in the glomerular capillary
wall, analogous to the mechanism by which linear
deposits develop in anti-GBM disease. Experimen-
tal MN, however, appears to differ from anti-GBM
disease with respect to the kinetics of antibody dep-
osition, the role of C3 and neutrophils in mediating
proteinuria, and the changes in the glomerular filtra-
tion barrier which result in increased permeability.
Although the role of in situ complex formation in
human glomerular disease is not known, the relative
infrequency with which CIC's have been demon-
strated in idiopathic MN, studies of glomerular
DNA binding in vitro, and characterization of anti-
DNA antibody levels and properties in patients
with SLE who develop membranous glomerular le-
sions support the hypothesis that some sub-
epithelial deposits in man may also form in situ.
Further definition of the mechanisms and frequency
of in situ glomerular immune deposit formation
promises to significantly extend current under-
standing of the pathogenesis of ICGN.
WILLIAM G. COUSER
DAVID J. SALANT
Boston
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